Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Allowing Compounding Pharmacies to Address Drug Shortages

Author(s):  Broughel James

Issue:  Mar/Apr 2022 - Volume 26, Number 2
View All Articles in Issue

Page(s):  100-109

Allowing Compounding Pharmacies to Address Drug Shortages Page 1
Allowing Compounding Pharmacies to Address Drug Shortages Page 2
Allowing Compounding Pharmacies to Address Drug Shortages Page 3
Allowing Compounding Pharmacies to Address Drug Shortages Page 4
Allowing Compounding Pharmacies to Address Drug Shortages Page 5
Allowing Compounding Pharmacies to Address Drug Shortages Page 6
Allowing Compounding Pharmacies to Address Drug Shortages Page 7
Allowing Compounding Pharmacies to Address Drug Shortages Page 8
Allowing Compounding Pharmacies to Address Drug Shortages Page 9
Allowing Compounding Pharmacies to Address Drug Shortages Page 10

Download in electronic PDF format for $75

Abstract:  The U.S. has entered a new age of supply chain challenges, and while many of these challenges were unpredictable consequences of the COVID-19 pandemic, there are also some predictable shortages, including those that arise in the modern prescription drug market. In an effort to combat these foreseeable events, compounding pharmacies, or compounders, have the wherewithal to step in and address drug shortages when they occur. Whether they are able to assist, however, ultimately hinges not on their capabilities, but on whether they are allowed to assist under federal law.

Related Keywords: James Broughel, PhD, drug shortages, supply chain, Covid-19 pandemic, public policy, U.S. Food and Drug Administration, FDA Guidance for Industry, Federal Food, Drug, and Cosmetic Act section 503A, Federal Food, Drug, and Cosmetic Act section 503B, American Society of Health Systems Pharmacists, legislation

Related Categories: LEGAL, SUPPORT, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
Mar/Apr 2022
Pg. 100-109

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
Jul/Aug 2020
Pg. 287-295

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry"
Allen Loyd V Jr
Mar/Apr 2022
Pg. 92

The Role of Compounding Pharmacists During Drug Shortages
Ofei Kelvin
Jul/Aug 2022
Pg. 298-301

Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Allen Loyd V Jr
, Williams LaVonn A
Jul/Aug 2012
Pg. 294-298

A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Brunner Scott
Jul/Aug 2021
Pg. 296-297

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

PreScription: COVID-19 and Compounding Pharmacists
Allen Loyd V Jr
Jul/Aug 2020
Pg. 268

PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again!
Allen Loyd V Jr
May/Jun 2023
Pg. 180

Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Lyon Joanna
Nov/Dec 2012
Pg. 456-460

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

Return to Top